Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy

Table 2

Breakdown of all emergent adverse events by body system. Data are number of subjects reporting event (number of events).

Body system disorder	Mother; 𝑛=142	Fetus; 𝑛=133	Baby; 𝑛=130
Reproductive, female	47 (68)	3 (3)
Gastrointestinal system	25 (37)		7 (7)
Body as a whole—general	20 (22)
Resistance mechanism	15 (19)		2 (2)
Cardiovascular—general	11 (14)
Urinary system	12 (14)
Central/peripheral nervous	12 (13)	1 (1)
Red blood cell	13 (13)
Respiratory system	9 (11)		4 (5)
Skin and appendages	6 (7)		2 (2)
Psychiatric	6 (7)
Metabolic and nutritional	3 (4)
Musculoskeletal system	2 (2)		1 (1)
Hearing and vestibular	2 (2)
Vascular (extracardiac)	2 (2)
Vision	1 (1)		1 (1)
Platelet, bleeding, and clotting	1 (1)
Foetal		12 (12)
Neonatal and infancy		2 (2)	7 (8)
Reproductive, male			1 (1)
Total	86 (237)	17 (18)	19 (27)